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Background. The rs12979860 CC genotype of the interleukin 28B (IL28B) polymorphism is associated with high rates of sustained
virological response (SVR) to peginterferon (PegIFN) and ribavirin (Rbv) in hepatitis C virus genotype-1 (HCV-1) patients. The
impact of baseline predictors of treatment outcome and their interplay with viral kinetics in HCV-1 CC patients has not been
fully evaluated. Aim. To identify baseline and on-therapy predictors of treatment failure in HCV-1 IL28B CC patients. Methods.
Treatment-na¨ıve HCV-1 patients, compliant to PegIFN and Rbvwho did not discontinue treatment for nonvirological reasons, were
analyzed. Results. 109 HCV-1 IL28B CC were studied. Sixty were males, 39 with BMI >25, 69 with >600,000 IU/mL HCV RNA, 15
withHCV1a, and 30 with cirrhosis. Overall, 75 (69%) achieved an SVR; cirrhosis was the only baseline predictor of treatment failure
(OR: 2.58, 95%CI: 1.07–6.21) as SVR rates were 53% in cirrhotics versus 75% in noncirrhotics (𝑃 = 0.03). HCVRNAundetectability
(<50 IU/mL) at week 4 (RVR) was achieved by 58 patients (53%). The SVR rates were independent of RVR in noncirrhotics, 76%
(34/45) RVR (+) and 74% (25/34) RVR (−) (𝑃 = 0.9). In cirrhotic patients, SVR rates were significantly higher in RVR (+) compared
to RVR (−) (10/13 (77%) versus 6/17 (35%)𝑃 = 0.03).Conclusions. InHCV-1 IL28BCC patients, cirrhosis is the only clinical baseline
predictor of PegIFN and Rbv treatment failure. However, in IL28B CC cirrhotics, the achievement of RVR identifies those patients
who still have high rates of SVR to Peg-IFN/Rbv therapy.
1. Introduction
Chronic infectionwith hepatitis C virus (HCV) affects almost
200 million people worldwide, representing a leading cause
of cirrhosis and anticipated liver-related death [1]. Until 2011,
treatment with pegylated interferon (PegIFN) and ribavirin
(Rbv) was the standard of care (SOC) for all HCV genotypes,
with HCV clearance depending both on virus and host-
related factors [2]. In the last year, the significant improve-
ment in sustained virological response (SVR) rates, attained
by the addition of the first generation of directly acting
antivirals (DAAs), the NS3 protease inhibitors Telaprevir or
Boceprevir, to PegIFN plus Rbv in the difficult to cure HCV
genotype 1 population, has created a new SOC for this group
of patients [3–5]. However, there are doubts whether univer-
sal treatment of HCV-1 patients with a DAA-based regimen
is cost-effective and safe, as DAAs including regimens are
associated with new treatment-related side effects, some of
which require expert management, many possible drug-drug
interactions, and the risk of developing resistant viral strains
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[6–8]. In this scenario, the single nucleotide polymorphism
(SNP) rs12979860 near the interleukin 28B (IL28B) region,
which has been identified as the strongest baseline predictor
of SVR to PegIFN plus Rbv in HCV-1 patients, has emerged
as key factor in the pretherapy algorithm [9, 10]. Indeed, the
high SVR rates obtained with PegIFN/Rbv in patients with
the favorable IL28B genotype (CC) question the need for
DAAs including regimens in these patients. Further sup-
porting such an assumption is a recent Markov model cost-
effectiveness analysis demonstrating that a DAA-based regi-
men does not provide added benefits over PegIFN/Rbv in this
subgroup of patients [11]. For these reasons, some scientific
societies have recommended that HCV-1 genotype IL28B CC
patients be offered PegIFN andRbv as a first-line therapy [12].
The only exemption being IL28B CC patients with cirrhosis,
where a DAA-based regimen is considered the SOC by most
guidelines due to a somewhat reduced efficacy of PegIFN
and Rbv in these patients. However, such IL28B guided
recommendations do not confer any clinical meaningfulness
to other baseline moderators of treatment failure in IL28B
CC patients nor do they value on-treatment viral kinetics
in these patients. This is extremely significant as HCV RNA
kinetics during treatment have been repeatedly shown to
possess a stronger predictive power in terms of treatment
outcome than any baseline pretreatment factor. With this as
a background, we investigated HCV-1 IL28B CC patients
treated with PegIFN plus Rbv to identify baseline and on-
treatment predictors of treatment outcome.
2. Materials and Methods
HCV-1 na¨ıve patients who received PegIFN plus Rbv therapy
in 5 clinical studies [13–17] conducted at the Liver Center
and the Metabolic Center for Liver Disease of the Ospedale
Maggiore Policlinico in Milan between 2003 and 2010 were
scrutinized. All patients consented to genetic testing andwere
genotyped for the IL28B rs12979860 SNP. Those with CT
or TT IL28B genotype and those with mixed HCV geno-
types excluded from this analysis. Patients who discontinued
PegIFN plus Rbv treatment for nonvirological reasons were
not adherent to antiviral therapy, or received less than 80% of
total PegIFN and Rbv expected doses were also excluded.
Chronic hepatitis C was defined by at least one year
serum positivity for serum HCV-RNA, ALT levels >1.5 times
the upper limit of normal, and by a liver biopsy, performed
in the year preceding treatment, consistent with chronic
hepatitis C. No patient was coinfected with hepatitis B virus
(HBV) or human immunodeficiency virus (HIV) or had
decompensated liver disease, drug dependence, or >20 g/day
alcohol intake. Patients gave their written informed consent
to receive therapy and tomake theirmedical records available
for this study which was approved by the Institutional Review
Board of the Department of Internal Medicine.
2.1. Measurements. Genomic DNA was obtained from whole
blood or peripheral blood mononuclear cells using the
QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany).
Genotyping of rs12979860 was performed using a 5󸀠nuclease
assay with allele-specific TaqMan probes, and assays were
run on a 7900HT real time PCR instrument (Applied Biosys-
tems, Carlsbad, CA, USA), following manufacturer’s instruc-
tion or by using the tetra primer ARMS method [18, 19].
Serum HCV-RNA was assessed by qualitative RT-PCR assay
(COBAS Amplicor HCV test version 2.0, Roche Diagnostics)
with a detection limit of 50 IU/mL, during treatment at
weeks 4, 12, 24, and 48 and after therapy at weeks 4, 12,
and 24. Serum HCV-RNA was quantified at baseline and
week 12 with Versant HCV-RNA 3.0 assay (bDNA 3.0, Bayer
Corporation, Emeryville, CA), with a sensitivity limit of
615 IU/mL and a dynamic range from615 to 7,700,000 IU/mL.
HCV was genotyped by line probe assay (INNO-LIPA HCV
2, Innogenetics, Zwijndrecht, Belgium). Liver biopsies were
performed with a 16 gauge Tru-Cut needle (Uro-Cut 16G,
TSK, Tokyo, Japan) and read by a single pathologist, who
was unaware of the patient’s identity and treatment regimen.
The severity of hepatic inflammation was evaluated by the
Ishak score, which conferred a maximum of 18 points for
grading (G) and 6 points for liver staging (S), so identifying
incomplete and complete cirrhosis as S 5 and 6, respectively.
2.2. Treatment. Patients received Rbv (Rebetol, Schering-
Plough Corporation, Kenilworth, NJ, USA) combined with
either PegIFN𝛼2a (Pegasys, Roche, Basel Switzerland)
180mcg/week or PegIFN𝛼2b 1.5mcg/Kg/week (PegIntron,
Schering-Plough Corporation) for 48 weeks. PegIFN𝛼2a
was associated with Rbv 1000–1200mg day (<75Kg; ≥75Kg)
while PegIFN𝛼2b was associated with Rbv 800mg for
patients of less than 65Kg body weight, 1000mg for 65–
85Kg, and 1200mg for ≥85Kg. Therapy was discontinued if
quantitative HCV-RNA testing at week 12 dropped by less
than 2Logs compared to baseline values and at week 24 if
HCV-RNA was still detectable in those patients in whom
HCV-RNA dropped >2 Log at week 12. All patients were
evaluated for safety and tolerance of treatment every 4 weeks
during the treatment period. PegIFN𝛼2a was reduced to
135mcg and PegIFN𝛼2b to 1.0mcg/Kg per week in patients
with <0.75 × 109/L neutrophils at two consecutive tests,
whereas it was withdrawn in patients with <0.50 × 109/L.
The same dose reductions were applied if platelets fell under
50,000 cells/mm3 with PegIFN being discontinued when
reaching the 25,000 cells/mm3 threshold. In both treatment
arms, Rbv dose was tapered by 200mg/day in patients
with haemoglobin <10 g/dL, whereas it was discontinued in
patients with <8.5 g/dL haemoglobin.
2.3. Definition of Response. Clearance of serum HCV-RNA
byRT-PCRwas assessed atweek 4 (rapid virological response,
RVR), at week 12 (complete early virological response, cEVR),
at week 24, and at week 48 of treatment (end of treatment
response, ETR). A sustained virological response (SVR) was
undetectable HCV-RNA by RT-PCR at week 24 after treat-
ment. Patients with an ETR who tested HCV-RNA positive
during followupwere classified as relapsers. Patients who had
any other virologic response were considered as nonrespon-
ders.
2.4. Statistical Analysis. Comparisons between groups were
made by using the Mann-Whitney U test or Student’s 𝑡-test
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Table 1: Baseline characteristics of the 109 HCV-1 rs12979860 CC
patients.
Patients Overall(𝑁 = 109)
Males 60 (55%)
Age, years (mean) 53 (range 24–70)
Weight, kg (mean) 68.4 (41–110)
BMI > 25 39 (36%)
Liver fibrosis stage (Ishak)
S 0–2 50 (46%)
S 3-4 29 (26%)
S 5-6 30 (28%)
HCV genotype
1b 94 (86%)
1a 15 (14%)
Baseline serum HCV-RNA
>0.6 × 106 IU/mL 69 (63%)
PegIFN type
alfa2a 50 (46%)
alfa2b 59 (54%)
for continuous variables and the𝜒2 or Fisher exact probability
test for categorical data. A probability value of 𝑃 < 0.05 was
considered statistically significant. Logistic regression anal-
ysis was performed to identify the variables associated with
PegIFN/Rbv treatment SVR. All variables with statistical
significance at the univariate analysis were included in the
final model, and odds ratios (OR) and corresponding 95%
confidence interval (95% CI) were computed. Calculations
were donewith Stata 10.0 statistical package (Stata 1944–2007,
College Station, TX, USA).
3. Results
Out of 409 HCV-1 patients enrolled in 5 clinical studies at
two liver centers andmeeting the inclusion criteria, 109 (27%)
were IL28BCC andwere included in the current analysis.The
clinical and epidemiological characteristics of the 109 patients
are shown in Table 1. 60 (55%) were males, the median age
was 53 years (range 24–70), and 47 (43%) patients were older
than 60 years. 39 (36%) patients had a BMI ≥25, and 30
(28%) had an histological diagnosis of cirrhosis (S 5, 6). Nine
patients (8%) were obese due to a BMI >30. The prevalence
of cirrhosis was independent of baseline BMI (BMI < 25:
17/70 (24%) versus BMI ≥ 25: 13/39 (33%), 𝑃 = ns). HCV
subtype was 1b in 94 (86%) and 1a in 15 patients (14%). 50
(46%) patients were treated with PegIFN𝛼-2a, while 59 (54%)
received PegIFN𝛼-2b.
3.1. Baseline Predictors of Treatment Outcome. Overall 75
(69%) patients achieved an SVR. Of the 34 patients with a
treatment failure, 3 (9%) were nonresponders while 31 (91%)
had a posttreatment relapse. Although SVR rates did not
significantly differ in the 5 clinical studies, they ranged from
64% to 76%.
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Figure 1: Treatment response rates stratified according to fibrosis
stage.
By univariate analysis, male gender, age, BMI > 25, HCV
viral load, and HCV-1 subtype did not influence SVR rates,
as the only baseline variable associated with treatment failure
was the presence of cirrhosis (OR 2.58, 95% CI 1.07–6.21)
(Table 2). Indeed, by stratifying SVR rates on the basis of
liver staging, cirrhotic patients achieved significantly lower
SVR rates than patients without cirrhosis ((16/30) 53% versus
(59/79) 75%, 𝑃 = 0.03).
Patients with cirrhosis showed numerically lower rates of
RVR, EVR, andETRandhigher rates of posttreatment relapse
compared to patients without cirrhosis (Figure 1). However,
this difference was marginally statistically significant only for
ETR rates (cirrhotics: 87% versus noncirrhotics: 97%, 𝑃 =
0.05).
3.2. On-Treatment Predictors. 58 (53%) patients achieved an
RVR, 99 (91%) an EVR, and 103 (95%) an ETR. Overall, the
achievement of an RVR did not significantly affect the SVR
rates, as the SVR rates were 76% in those with an RVR and
61% in those without an RVR (𝑃 = 0.1).
However, when stratifying patients by liver fibrosis stag-
ing, RVR emerged as a predictor of treatment outcome in
those with cirrhosis. Indeed, in noncirrhotic patients the
SVR rates remained homogenously high independently of the
achievement of an RVR, 76% (34/45) in RVR (+) compared
to 74% (25/34) in RVR (−) (𝑃 = 0.9). On the other hand,
in patients with cirrhosis, the achievement of an RVR was
associated with significantly higher SVR rates compared to
those obtained in patients who failed to achieve an RVR, SVR
being, respectively, 77% (10/13) in RVR (+) and 35% (6/17)
in RVR (−) (𝑃 = 0.03), hence identifying RVR as a strong
predictor of SVR in these patients (OR 6.1, 95% CI: 1.2–31.2)
(Figure 2).
4. Discussion
Our study shows that cirrhosis is the only baseline predictor
of treatment failure in HCV-1 IL28B CC patients, with 53% of
cirrhotic patients achieving an SVR compared to 75% of non-
cirrhotics. Our data do not only partially replicate a previous
subanalysis of the IDEAL study, showing lower SVR rates in
IL28B CC patients with bridging fibrosis and cirrhosis [10],
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Table 2: Epidemiological and clinical characteristics stratified by treatment outcome.
SVR (𝑛 = 75) Non-SVR(𝑛 = 34) 𝑃 value
∗ OR for non-SVR
(95% CI)
Male sex, 𝑛 (%) 41 (55%) 19 (56%) 1 1.05 (0.46–2.37)
Age, years (median) 56 60 0.19 1.02 (0.99–1.07)
BMI > 25, 𝑛 (%) 24 (32%) 15 (44%) 0.29 1.66 (0.73–3.86)
HCV-1a, 𝑛 (%) 13 (18%) 2 (6%) 0.13 0.29 (0.06–1.40)
High viral load, 𝑛 (%)∘ 44 (59%) 25 (85%) 0.2 1.95 (0.80–4.76)
Cirrhosis, 𝑛 (%) 16 (21%) 14 (41%) 0.03 2.58 (1.07–6.21)
PegIFN alfa-2a, 𝑛 (%) 38 (51%) 12 (41%) 0.15 0.53 (0.23–1.22)
∗Mann-Whitney 𝑈 test for continuous variables, Fisher’s exact test for categorical variables.
∘Baseline serum HCV RNA > 0.6 × 106 IU/mL.
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Figure 2: SVR rates stratified by fibrosis stage and RVR.
but add nicely to that study by showing the importance of on-
treatment viral kinetics in these patients. The achievement of
an RVR in cirrhotic patients was associated with high rates
of SVR (77%), which contrast with the low SVR rates (35%)
in cirrhotic patients who were still HCV RNA positive after
4 weeks of treatment. This is a novel finding since several
studies have shown RVR to lose its strong predictive power
in IL28B CC patients of any HCV genotype [20, 21]. Indeed,
although CC patients are more prone than patients with the
T allele to achieve an RVR, the SVR rates remain high also in
the subgroup of CC patients that do not reach this endpoint.
This was recently magnified by a study analyzing the benefit
of treatment extension to 72 weeks in HCV-1 and 4 slow
responders, which reported no significant increase in SVR
rates in IL28B CC patients mainly as a direct cause of the
satisfactory SVR rates obtained by the standard 48-week
treatment regimen [22]. Our study confirms this observation
but only in those without cirrhosis, as in this subgroup the
SVR rates were independent of RVR status. Although this
findingmight be at least in part related to the low sensitivity of
our HCV RNA assay, this data nicely replicates findings from
a previous study using an HCV RNA assay with an LOD of
27 IU/mL [10].
On the other hand, RVR did play a key role in predicting
treatment outcome in IL28B CC patients with cirrhosis,
as SVR rates were surprisingly low in those not reaching
this virological landmark. Although we cannot provide a
definitive explanation for this interplay, it is probable that,
in the setting of an altered liver architecture with a deranged
microcirculation due to fibrosis deposition [23], whichmight
impair PegIFN/Rbv antiviral effect [24], the achievement of
an RVR identifies a subgroup of patients still able to activate
the complex pathways necessary to define an antiviral state,
which ultimately results in persistent viral eradication also in
the presence of cirrhosis.
While this hypothesis further reinforces the dominant
role of RVR over pretreatment variables as the most pow-
erful predictor of SVR, our characterization of the inter-
play between fibrosis staging and on-treatment kinetics has
important clinical implications. Since a universal migration
to DAA-based regimens in all HCV-1 patients might not be
affordable in terms of healthcare resources in countries where
a welfare state is in place, correct selection of patients for
a DAA-based regimen is mandatory. In Europe, most, local
guidelines suggest offeringHCV-1 patientswith the IL28BCC
genotype, PegIFN/Rbv as the first-choice therapy, while offer-
ing a DAA-based regimen only to IL28B CC patients with
advanced fibrosis/cirrhosis [6, 12, 25, 26]. From this point of
view, our findings suggest the need for better stratification in
cirrhotic patients, as this subset of patients likely represents
themost prone to suffer from side effects withDAA regimens,
does not benefit from response guided treatment duration
with these drugs, as cirrhotic patients require in all cases 48
weeks of treatment, and ultimately might be potentially more
harmed by the development of drug resistances. Based on
our results, the combination of IL28B genotype and HCV-
RNA testing after 4 weeks of treatment could improve the
decision making process, as a four-week PegIFN/Rbv lead-
in phase in IL28B CC cirrhotic patients could discriminate
those requiring the addition of a DAA from those who could
continue with dual therapy. Our proposal in theory would
contrast with the fact that only boceprevir has been registered
with a lead-in phase, de facto limiting this new algorithm to
just one of the newDAAs; still several expert opinions suggest
that a lead-in phase can be safely and effectively applied to
telaprevir regimens too [3–5, 27]. While in theory such an
approach would seem cost effective over universal treatment
with DAAs, it needs to be validated in a cost effectiveness
analysis taking into account indirect costs such as IL28B
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testing and availability as well as fibrosis staging through liver
biopsy or noninvasive methods.
We acknowledge that our study has several limitations;
first of all it is retrospective, and it includes only patients
who were adherent to the optimal treatment schedule and
were enrolled in 5 clinical studies where both PegIFNs were
administered. Given the different efficacy of the two regimens
reported by us and others [13, 28] and the different sensitivity
to degree of fibrosis reported in some studies [24], this
calls for external validation of our results in large cohorts
of patients receiving both PegIFNs. Moreover, due to the
extended enrolment period, the PCR assay used in our study
for on-treatment serum HCV-RNA assessment had a rela-
tively high limit of detection (50 IU/mL) that could havemis-
classified some RVR patients and suggests validation of our
results with an HCV RNA assay with a lower detection limit
[29, 30]. Lastly, in our study cirrhosis was histologically
defined, a practice that is common in clinical trials but less
so in everyday clinical practice, due to the reliability of
noninvasive methods to assess liver fibrosis (i.e., transient
elastography) [31]. However, since noninvasive methods are
known to be negatively influenced in terms of accuracy and
reproducibility by being overweight or obese, something that
we reported in 36% of our cohort of patients, liver biopsy is
likely to remain essential in any treatment-related algorithm
guided by fibrosis staging [32].Most importantly, our patients
with cirrhosis were all Child-Pugh A5, had in all cases a
platelet count >75 × 103/mm3 (range 90–260 × 103/mm3),
and had esophageal varices in just 1 case (3%), stressing
the concept that our data apply only to well-compensated
cirrhotics without clinical stigmas of portal hypertension.
Notwithstanding these limitations, our demonstration of
an interplay between cirrhosis and RVR in IL28B CC patients
provides evidence for individualized treatment algorithms
also in this subgroup of highly responsive patients.
Abbreviations
HCV: Hepatitis C virus
IL28B: Interleukin 28B
SVR: Sustained virological response
PegIFN: Peginterferon
Rbv: Ribavirin
RVR: Rapid virological response
DAA: Directly acting antivirals
SNP: Single nucleotide polymorphism
HBV: Hepatitis B virus
HIV: Human immunodeficiency virus
cEVR: Complete early virological response
ETR: End of treatment response
OR: Odds ratios
95% CI: 95% confidence interval.
Acknowledgments
Massimo Colombo, M.D., received grant and research sup-
port from Merck, Roche, BMS, and Gilead Science; advisory
committees: Merck, Roche, Novartis, Bayer, BMS, Gilead
Science, Tibotec, Vertex, Janssen Cilag, Achillion, Lundbeck,
Abbott, and Boehringer Ingelheim; speaking and teaching:
Tibotec, Roche, Novartis, Bayer, BMS, Gilead Science, and
Vertex. Alessio Aghemo, M.D., received grant and research
support fromRoche andGilead Sciences; speaking and teach-
ing: Roche, Janssen, andMerck; travel support: BMS, Janssen,
Roche, and Merck. Maria Grazia Rumi, M.D., received travel
support fromRoche; speaking and teaching: Roche and BMS;
advisory committees: Janssen. RaffaeleDe Francesco received
consulting fees from Boehringer Ingelheim and Rottapharm
Madaus. Other authors have no financial disclosure to
declare. The paper was supported by a research grant from
Roche.
References
[1] European Association for the Study of the Liver, “EASL Clinical
PracticeGuidelines:management of hepatitis C virus infection,”
Journal of Hepatology, vol. 55, pp. 245–264, 2011.
[2] E. Degasperi and A. Aghemo, “Clinical drivers in na¨ıve patient
eligibility for treatment of chronic hepatitis C,” Journal of Viral
Hepatitis, vol. 19, no. 1, pp. 3–6, 2012.
[3] I. M. Jacobson, J. G. McHutchison, G. Dusheiko et al., “Telapre-
vir for previously untreated chronic hepatitis C virus infection,”
TheNew England Journal ofMedicine, vol. 364, no. 25, pp. 2405–
2416, 2011.
[4] F. Poordad, J. McCone Jr., B. R. Bacon et al., “Boceprevir for
untreated chronic HCV genotype 1 infection,”TheNew England
Journal of Medicine, vol. 364, no. 13, pp. 1195–1206, 2011.
[5] M.G. Ghany, D. R. Nelson, D. B. Strader, D. L.Thomas, and L. B.
Seeff, “An update on treatment of genotype 1 chronic hepatitis C
virus infection: 2011 practice guideline by the American Asso-
ciation for the Study of Liver Diseases,” Hepatology, vol. 54, no.
4, pp. 1433–1444, 2011.
[6] A. Aghemo, E. Degasperi, and M. Colombo, “Directly acting
antivirals for the treatment of chronic hepatitis C: unresolved
topics from registration trials,” Digestive and Liver Disease, vol.
45, no. 1, pp. 1–7, 2013.
[7] C. Camma`, S. Petta, M. Enea et al., “Cost-effectiveness of boce-
previr or telaprevir for untreated patients with genotype 1
chronic hepatitis C,” Hepatology, vol. 56, no. 3, pp. 850–860,
2012.
[8] S. Liu, L. E. Cipriano, M. Holodniy, D. K. Owens, and J. D.
Goldhaber-Fiebert, “New protease inhibitors for the treatment
of chronic hepatitis C: a cost-effectiveness analysis,” Annals of
Internal Medicine, vol. 156, no. 4, pp. 279–290, 2012.
[9] D. Ge, J. Fellay, A. J. Thompson et al., “Genetic variation in
IL28B predicts hepatitis C treatment-induced viral clearance,”
Nature, vol. 461, no. 7262, pp. 399–401, 2009.
[10] A. J. Thompson, A. J. Muir, M. S. Sulkowski et al., “Interleukin-
28B polymorphism improves viral kinetics and is the strongest
pretreatment predictor of sustained virologic response in geno-
type 1 hepatitis C virus,” Gastroenterology, vol. 139, no. 1, pp.
120.e18–129.e18, 2010.
[11] Z. F. Gellad, S. Naggie, S. D. Reed et al., “The cost-effectiveness
of a telaprevir inclusive regimen as initial therapy for genotype
1 hepatitis C infection in individuals with the CC IL28B
polymorphism,” Hepatology, vol. 54, S1, A118, 2011.
[12] P. Ramachandran, A. Fraser, K. Agarwal et al., “UK consensus
guidelines for the use of the protease inhibitors boceprevir and
telaprevir in genotype 1 chronic hepatitis C infected patients,”
Alimentary Pharmacology and Therapeutics, vol. 35, no. 6, pp.
647–662, 2012.
6 BioMed Research International
[13] A. Aghemo, M. G. Rumi, S. Monico et al., “The pattern of pegy-
lated interferon-𝛼2b and ribavirin treatment failure in cirrhotic
patients depends on hepatitis C virus genotype,” Antiviral Ther-
apy, vol. 14, no. 4, pp. 577–584, 2009.
[14] M. G. Rumi, A. Aghemo, G. M. Prati et al., “Randomized Study
of peginterferon-𝛼2a plus ribavirin vs peginterferon-𝛼2b plus
ribavirin in chronic hepatitis C,” Gastroenterology, vol. 138, no.
1, pp. 108–115, 2010.
[15] L. Valenti,M. Rumi, E. Galmozzi et al., “Patatin-Like phospholi-
pase domain-containing 3 I148M polymorphism, steatosis, and
liver damage in chronic hepatitis C,” Hepatology, vol. 53, no. 3,
pp. 791–799, 2011.
[16] F. Marabita, A. Aghemo, S. de Nicola et al., “Genetic variation
in the interleukin-28B gene is not associated with fibrosis
progression in patients with chronic hepatitis C and known date
of infection,” Hepatology, vol. 54, no. 4, pp. 1127–1134, 2011.
[17] P. J. Clark, A. Aghemo, E. Degasperi et al., “Inosine triphos-
phatase deficiency helps predict anaemia, anaemia manage-
ment and response in chronic hepatitis C therapy,” Journal of
Viral Hepatitis, 2013.
[18] E. Galmozzi, B. D. Menico, R. Rametta et al., “A tetra-primer
amplification refractory mutation system polymerase chain
reaction for the evaluation of rs12979860 IL28B genotype,”
Journal of Viral Hepatitis, vol. 18, no. 9, pp. 628–630, 2011.
[19] B. M. Motta, P. Dongiovanni, S. Fargion, and L. Valenti, “T-
ARMS-PCR for the evaluation of rs12979860 IL28B genotype:
an optimized protocol,” Journal of Viral Hepatitis, vol. 19, no. 3,
article 228, 2012.
[20] A. Mangia, A. J. Thompson, R. Santoro et al., “An IL28B poly-
morphism determines treatment response of hepatitis C virus
genotype 2 or 3 patients who do not achieve a rapid virologic
response,” Gastroenterology, vol. 139, no. 3, pp. 821.e1–827.e1,
2010.
[21] S. De Nicola, A. Aghemo, M. Grazia Rumi et al., “Interleukin
28B polymorphism predicts pegylated interferon plus ribavirin
treatment outcome in chronic hepatitis C genotype 4,”Hepatol-
ogy, vol. 55, no. 2, pp. 336–342, 2012.
[22] T.-M. Scherzer, A. F. Sta¨ttermayer, M. Strasser et al., “Impact of
IL28B on treatment outcome in hepatitis C virus G1/4 patients
receiving response-guided therapy with peginterferon alpha-
2a (40KD)/ribavirin,” Hepatology, vol. 54, no. 5, pp. 1518–1526,
2011.
[23] R. D’Ambrosio, A. Aghemo,M.G. Rumi et al., “Amorphometric
and immunohistochemical study to assess the benefit of an svr
in hcv cirrhotic patients,”Hepatology, vol. 56, no. 2, pp. 532–543,
2012.
[24] G.M. Prati, A.Aghemo,M.G. Rumi et al., “Hyporesponsiveness
to PegIFN𝛼2B plus ribavirin in patients with hepatitis C-related
advanced fibrosis,” Journal of Hepatology, vol. 56, no. 2, pp. 341–
347, 2012.
[25] C. Sarrazin, T. Berg, M. Cornberg et al., “Expert opinion on
Boceprevir- and Telaprevir-based triple therapies of chronic
hepatitis C,” Zeitschrift fur Gastroenterologie, vol. 50, no. 1, pp.
57–72, 2012.
[26] “AISF position paper on the use of triple therapy with a
protease inhibitor in patients with chronic hepatitis C geno-
type 1,” 2012, http://www.webaisf.org/media/14647/position
-paper-definitivo-26-01-12.pdf. .
[27] S. Bruno and A. Mangia, “Futility of antiviral treatments for
hepatitis C: an evolving concept entering the direct antiviral
agents era,” Digestive and Liver Disease, vol. 45, no. 5, pp. 356–
361, 2013.
[28] T. Awad, K. Thorlund, G. Hauser, D. Stimac, M. Mabrouk, and
C. Gluud, “Peginterferon alpha-2a is associated with higher sus-
tained virological response than peginterferon alfa-2B in chron-
ic hepatitis C: systematic review of randomized trials,”Hepatol-
ogy, vol. 51, no. 4, pp. 1176–1184, 2010.
[29] C. Sarrazin, M. L. Shiffman, S. J. Hadziyannis et al., “Definition
of rapid virologic response with a highly sensitive real-time
PCR-based HCV RNA assay in peginterferon alfa-2a plus rib-
avirin response-guided therapy,” Journal of Hepatology, vol. 52,
no. 6, pp. 832–838, 2010.
[30] J. Vermehren, A. Aghemo, S. Susser et al., “Differences in HCV
genotype 1 RVR rates among clinical trials in Europe depend on
HCV RNA assay sensitivity,” Journal of Hepatology, vol. 56, no.
S2, p. S364, 2012.
[31] M. Fraquelli, C. Rigamonti, G. Casazza et al., “Reproducibility
of transient elastography in the evaluation of liver fibrosis in
patients with chronic liver disease,” Gut, vol. 56, no. 7, pp. 968–
973, 2007.
[32] L. Castera, “Noninvasive methods to assess liver disease in
patients with hepatitis B or C,” Gastroenterology, vol. 142, no.
6, pp. 1293.e4–1302.e4, 2012.
